image
Healthcare - Medical - Pharmaceuticals - NASDAQ - CN
$ 8.0
1.2 %
$ 69.3 M
Market Cap
-3.69
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one YI stock under the worst case scenario is HIDDEN Compared to the current market price of 8 USD, 111, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one YI stock under the base case scenario is HIDDEN Compared to the current market price of 8 USD, 111, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one YI stock under the best case scenario is HIDDEN Compared to the current market price of 8 USD, 111, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart YI

image
$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
14.4 B REVENUE
-3.66%
2.11 M OPERATING INCOME
100.60%
-20.8 M NET INCOME
94.12%
263 M OPERATING CASH FLOW
158.81%
37.4 M INVESTING CASH FLOW
-75.37%
-406 M FINANCING CASH FLOW
-197.22%
3.85 B REVENUE
6.86%
-7.32 M OPERATING INCOME
-308.69%
-19.8 M NET INCOME
0.00%
-48.5 M OPERATING CASH FLOW
-44.19%
37.5 M INVESTING CASH FLOW
-24.73%
-35.8 M FINANCING CASH FLOW
67.62%
Balance Sheet 111, Inc.
image
Current Assets 2.65 B
Cash & Short-Term Investments 462 M
Receivables 631 M
Other Current Assets 1.56 B
Non-Current Assets 138 M
Long-Term Investments 0
PP&E 122 M
Other Non-Current Assets 16.1 M
16.58 %22.62 %55.84 %4.38 %Total Assets$2.8b
Current Liabilities 2.34 B
Accounts Payable 1.72 B
Short-Term Debt 201 M
Other Current Liabilities 420 M
Non-Current Liabilities 64.4 M
Long-Term Debt 55.4 M
Other Non-Current Liabilities 8.96 M
71.52 %8.36 %17.44 %Total Liabilities$2.4b
EFFICIENCY
Earnings Waterfall 111, Inc.
image
Revenue 14.4 B
Cost Of Revenue 13.6 B
Gross Profit 829 M
Operating Expenses 827 M
Operating Income 2.11 M
Other Expenses 22.9 M
Net Income -20.8 M
16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b00(2b)(2b)14b(14b)829m(827m)2m(23m)(21m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
5.76% GROSS MARGIN
5.76%
0.01% OPERATING MARGIN
0.01%
-0.45% NET MARGIN
-0.45%
10.07% ROE
10.07%
-2.32% ROA
-2.32%
0.33% ROIC
0.33%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis 111, Inc.
image
300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)(700m)(700m)(800m)(800m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -20.8 M
Depreciation & Amortization 17 M
Capital Expenditures -15.2 M
Stock-Based Compensation 20.1 M
Change in Working Capital 193 M
Others -36.1 M
Free Cash Flow 248 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets 111, Inc.
image
YI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership 111, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
111, Inc. Announces First Quarter 2025 Unaudited Financial Results Maintained Quarterly Operational Profitability Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY Maintained Quarterly Positive Operating Cash Flow SHANGHAI , June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net revenues were RMB3.5 billion (US$486.3 million), remaining relatively flat compared to the same quarter last year. prnewswire.com - 2 weeks ago
111, Inc. (YI) Q4 2024 Earnings Call Transcript 111, Inc. (NASDAQ:YI ) Q4 2024 Earnings Conference Call March 20, 2025 7:30 AM ET Company Participants Junling Liu - Co-Founder, Chairman and Chief Executive Officer Luke Chen - Chief Financial Officer Haihui Wang - Chief Operating Officer Conference Call Participants Robert Sassoon - Water Tower Research Shifan Sun - CICC Zoe Bian - Citi Operator Hello, everyone, and thank you for joining 111's Conference Call today. On the call today from the company are Dr. Gang Yu, Co-Founder and Executive Chairman; Mr. seekingalpha.com - 3 months ago
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results Achieved First-Ever Annual Operating Profit Bottom Line Improved by RMB332.7 Million YoY in 2024 Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoY Achieved First-Ever Annual Positive Operating Cash Flow SHANGHAI , March 20, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Highlights Net revenues were RMB3.8 billion (US$527.1 million) and gross segment profit (1) was RMB202.5 million (US$27.7 million). prnewswire.com - 3 months ago
111, Inc. to Participate in Fireside Chat with Water Tower Research on March 26, 2025 SHANGHAI , March 12, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research ("WTR") on Wednesday, March 26, 2025 at 11:00 a.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's Q4 2024 earnings (to be reported on Thursday, March 20, 2024), its priorities and goals for 2025, and an updated overview of the macroenvironment. prnewswire.com - 3 months ago
111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow SHANGHAI , Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2024 ended December 31, 2024, before the U.S. market opens on Thursday, March 20, 2025. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 20, 2025 (7:30 PM Beijing Time on the same day). prnewswire.com - 4 months ago
111, Inc. Regains Compliance with NASDAQ Requirement SHANGHAI , Feb. 11, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a  leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced today that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") on February 10, 2025, confirming that Nasdaq has determined that for the last ten consecutive business days, from January 24, 2025 to February 7, 2025, the closing bid price of the Company's American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1). prnewswire.com - 4 months ago
Compound Semiconductor Market to surpass USD 111.6 billion by 2032, Says Global Market Insights inc. Compound Semiconductor Industry size is expected to register 10.9% CAGR between 2024 and 2032 propelled by electric vehicles and renewable energy. Compound Semiconductor Industry size is expected to register 10.9% CAGR between 2024 and 2032 propelled by electric vehicles and renewable energy. globenewswire.com - 5 months ago
111, Inc. Announces ADS Ratio Change SHANGHAI , Jan. 8, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to Class A ordinary shares from one (1) ADS representing two (2) Class A ordinary shares to the new ratio of one (1) ADS representing twenty (20) Class A ordinary shares. For the Company's ADS holders, this ratio change will have the same effect as a one-for-ten reverse ADS split. prnewswire.com - 5 months ago
111, Inc. (YI) Q3 2024 Earnings Call Transcript 111, Inc. (NASDAQ:YI ) Q3 2024 Results Conference Call November 27, 2024 7:30 AM ET Company Participants Dr. Gang Yu - Co-Founder and Executive Chairman Junling Liu - Co-Founder, Chairman and Chief Executive Officer Luke Chen - Chief Financial Officer Haihui Wang - Chief Operating Officer Conference Call Participants Jessie Lu - HSBC Robert Sassoon - Water Tower Research Operator Hello, everyone, and thank you for joining 111's Conference Call today. On the call today from the Company are Dr. Gang Yu, Co-Founder and Executive Chairman; Mr. seekingalpha.com - 7 months ago
111, Inc. Announces Third Quarter 2024 Unaudited Financial Results Maintained Operational Profitability for the Third Consecutive Quarter Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI , Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same quarter last year. prnewswire.com - 7 months ago
111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024 SHANGHAI , Nov. 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research ("WTR") on Friday, December 6, 2024 at 11:00 a.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's Q3 2024 earnings (to be reported on Wednesday, November 27, 2024), along with challenges, opportunities, and the NASDAQ share price compliance issue. prnewswire.com - 7 months ago
111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow SHANGHAI , Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that its release of unaudited financial results for the third quarter ended September 30, 2024, previously scheduled for Thursday, November 28, 2024, will now occur before the U.S. market opens on Wednesday, November 27, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Wednesday, November 27, 2024 (8:30 PM Beijing Time on the same day). prnewswire.com - 7 months ago
8. Profile Summary

111, Inc. YI

image
COUNTRY CN
INDUSTRY Medical - Pharmaceuticals
MARKET CAP $ 69.3 M
Dividend Yield 0.00%
Description 111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. As of December 31, 2021, it operated 14 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan provinces. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Contact No.295 ZuChongZhi Road, Shanghai, 201203 https://www.111.com.cn
IPO Date Sept. 12, 2018
Employees 1238
Officers Mr. Alex Liu Finance Director Monica Mu IR Director Mr. Anfeng Guo Chief Innovation Officer Dr. Gang Yu Ph.D. Co-Founder & Executive Chairman Mr. Junling Liu Co-Founder, Acting Chief Financial Officer, Chairman & Chief Executive Officer Mr. Haihui Wang Co-Chief Operating Officer Mr. Pengcheng Zhu Co-Chief Operating Officer